pamidronate has been researched along with Fibrous Dysplasia, Polyostotic in 25 studies
Fibrous Dysplasia, Polyostotic: FIBROUS DYSPLASIA OF BONE affecting several bones. When melanotic pigmentation (CAFE-AU-LAIT SPOTS) and multiple endocrine hyperfunction are additionally associated it is referred to as Albright syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function." | 9.10 | Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002) |
| "Four infant outcomes of pregnancies of three women, two with polyostotic fibrous dysplasia and one with osteogenesis imperfecta, all of whom were treated with iv pamidronate before conception, are reported, with biochemical, radiological, and bone density data." | 7.73 | Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. ( Chan, B; Zacharin, M, 2006) |
| "An open trial of pamidronate treatment was undertaken in 5 children and 4 young adults with polyostotic fibrous dysplasia associated with McCune Albright syndrome to assess clinical response, bone turnover, and cardiovascular status over a 2-year period." | 7.70 | Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. ( O'Sullivan, M; Zacharin, M, 2000) |
| "Pamidronate treatment can ameliorate the course of bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome." | 6.69 | Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. ( Bertelloni, S; Buzi, F; de Sanctis, C; Lala, R; Matarazzo, P; Rigon, F, 2000) |
| "Pamidronate appears to be an effective and well tolerable treatment option for patients with fibrous dysplasia." | 5.30 | [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome]. ( Pfeilschifter, J; Ziegler, R, 1998) |
| "Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function." | 5.10 | Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002) |
| "ALP = alkaline phosphatase; β-CTX = C-terminal telopeptide of type I collagen; BP = bisphosphonate; BTM = bone turnover marker; FD = fibrous dysplasia; MAS = McCune-Albright syndrome; ONJ = osteonecrosis of the jaw; PAM = pamidronate; PFD = polyostotic fibrous dysplasia; ULN = upper limit of normal; ZA = zoledronic acid." | 3.91 | EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE. ( Jiang, Y; Li, M; Meng, X; Wang, O; Wang, Y; Xia, W; Xing, X, 2019) |
| " We report here on a child with McCune-Albright syndrome (FD in addition to hyperfunctioning endocrinopathies and skin hyperpigmentation) treated with cyclical intravenous infusions of pamidronate in which conventional radiography, contact microradiography, histology, and backscattered electron image analysis demonstrated that zebra lines formed only where bone was normal, were arrested at the boundary between FD-unaffected and FD-affected bone where bone is sclerotic, and were absent within the undermineralized FD bone." | 3.85 | Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome. ( Boyde, A; Corsi, A; Ippolito, E; Riminucci, M; Robey, PG, 2017) |
| "To examine outcomes of pamidronate treatment on fibrous dysplasia of bone in three children with McCune-Albright syndrome (MAS)." | 3.73 | Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood. ( Chan, B; Zacharin, M, 2006) |
| "Four infant outcomes of pregnancies of three women, two with polyostotic fibrous dysplasia and one with osteogenesis imperfecta, all of whom were treated with iv pamidronate before conception, are reported, with biochemical, radiological, and bone density data." | 3.73 | Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. ( Chan, B; Zacharin, M, 2006) |
| "Intravenous infusions with the bisphosphonate compound pamidronate decrease bone pain and reportedly can lead to refilling of dysplastic lesions in adults with fibrous dysplasia (FD) of bone." | 3.72 | Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. ( Glorieux, FH; Munns, C; Plotkin, H; Rauch, F; Travers, R; Zeitlin, L, 2003) |
| "An open trial of pamidronate treatment was undertaken in 5 children and 4 young adults with polyostotic fibrous dysplasia associated with McCune Albright syndrome to assess clinical response, bone turnover, and cardiovascular status over a 2-year period." | 3.70 | Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. ( O'Sullivan, M; Zacharin, M, 2000) |
| "One of the main features of McCune-Albright syndrome is bone fibrous dysplasia (BFD) often associated with severe clinical outcomes, such as bone pain, bone deformities and pathological fractures." | 2.72 | Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. ( Andreo, M; Bellone, J; Corrias, A; de Sanctis, C; Lala, R; Marzari, D; Matarazzo, P, 2006) |
| "Pamidronate treatment can ameliorate the course of bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome." | 2.69 | Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. ( Bertelloni, S; Buzi, F; de Sanctis, C; Lala, R; Matarazzo, P; Rigon, F, 2000) |
| "Fibrous dysplasia of bone is a genetic, non-inheritable disease, characterized by bone pain, bone deformities and fracture, involving one or several bones." | 2.44 | Fibrous dysplasia of bone and McCune-Albright syndrome. ( Chapurlat, RD; Orcel, P, 2008) |
| "Fibrous dysplasia of bone is a disease that can involve one or several bones and is characterized by bone deformities, pain and iterative fractures." | 2.41 | Fibrous dysplasia of bone. ( Chapurlat, RD; Meunier, PJ, 2000) |
| "McCune-Albright syndrome (MAS) typically comprises the constellation of polyostotic fibrous dysplasia, café-au-lait spots, and associated endocrinopathies including gonadotropin-independent precocious puberty, excessive growth hormone production and gigantism, hyperthyroidism, and hyperparathyroidism." | 1.36 | Unusual phenotypical variations in a boy with McCune-Albright syndrome. ( Anhalt, H; Mamkin, I; Philibert, P; Sultan, C; Ten, S, 2010) |
| "McCune-Albright syndrome (MAS) is sometimes complicated by hypophosphatemia and abnormally low levels of 1,25(OH)(2)D in the presence of hypophosphatemia." | 1.33 | The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. ( Imanishi, Y; Inaba, M; Jüppner, H; Kinoshita, E; Koshiyama, H; Miyauchi, A; Nakagomi, Y; Nishizawa, Y; Ozono, K; Satomura, K; Shimizu, N; Yamamoto, T, 2005) |
| "We describe a rare case of polyostotic fibrous dysplasia with craniofacial localisation associated with the involvement of the humerus in a 65-year-old female patient." | 1.33 | [A case of polyostotic fibrous dysplasia]. ( Jaworska, M; Klempous, J; Kuźniar, J; Sztuka, A, 2006) |
| "pamidronate was given for 6 months." | 1.31 | [Fibrous dysplasia: differential diagnosis from Paget's disease]. ( Heilmann, P; Kasperk, Ch; Nawroth, P; Schulz, A; Wagner, P, 2002) |
| "McCune-Albright syndrome is a rare syndrome presenting with polyostotic dysplasia, cafe-au-lait spots and multiple endocrinopathies that is very often combined with precocious puberty." | 1.31 | Clinical, endocrinological and radiography features in a child with McCune-Albright syndrome and pituitary adenoma. ( Jassoy, A; Lebek, S; Nagel, M; Zumkeller, W, 2001) |
| "Pamidronate appears to be an effective and well tolerable treatment option for patients with fibrous dysplasia." | 1.30 | [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome]. ( Pfeilschifter, J; Ziegler, R, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 17 (68.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bachelet, JT | 1 |
| Mendes, LC | 1 |
| Delafond, C | 1 |
| Barba, T | 1 |
| Gleizal, A | 1 |
| Paulus, C | 1 |
| Corsi, A | 1 |
| Ippolito, E | 1 |
| Robey, PG | 1 |
| Riminucci, M | 1 |
| Boyde, A | 1 |
| Wang, Y | 1 |
| Wang, O | 1 |
| Jiang, Y | 1 |
| Li, M | 1 |
| Xia, W | 1 |
| Meng, X | 1 |
| Xing, X | 1 |
| Couturier, A | 1 |
| Aumaître, O | 1 |
| Gilain, L | 1 |
| Jean, B | 1 |
| Mom, T | 1 |
| André, M | 1 |
| Mamkin, I | 1 |
| Philibert, P | 1 |
| Anhalt, H | 1 |
| Ten, S | 1 |
| Sultan, C | 1 |
| Kochar, IP | 1 |
| Kulkarni, KP | 1 |
| Rastogi, A | 1 |
| Bhadada, SK | 1 |
| Bhansali, A | 1 |
| Matarazzo, P | 4 |
| Lala, R | 4 |
| Masi, G | 1 |
| Andreo, M | 3 |
| Altare, F | 1 |
| de Sanctis, C | 4 |
| Isaia, GC | 1 |
| Defilippi, C | 1 |
| Roggia, C | 1 |
| Priolo, G | 1 |
| Wagner, P | 1 |
| Heilmann, P | 1 |
| Schulz, A | 1 |
| Nawroth, P | 1 |
| Kasperk, Ch | 1 |
| Saenger, P | 1 |
| Rincon, M | 1 |
| Plotkin, H | 1 |
| Rauch, F | 1 |
| Zeitlin, L | 1 |
| Munns, C | 1 |
| Travers, R | 1 |
| Glorieux, FH | 1 |
| Yamamoto, T | 1 |
| Imanishi, Y | 1 |
| Kinoshita, E | 1 |
| Nakagomi, Y | 1 |
| Shimizu, N | 1 |
| Miyauchi, A | 1 |
| Satomura, K | 1 |
| Koshiyama, H | 1 |
| Inaba, M | 1 |
| Nishizawa, Y | 1 |
| Jüppner, H | 1 |
| Ozono, K | 1 |
| Chan, B | 2 |
| Zacharin, M | 3 |
| Klempous, J | 1 |
| Kuźniar, J | 1 |
| Sztuka, A | 1 |
| Jaworska, M | 1 |
| Bieniasz, J | 1 |
| Maj, A | 1 |
| Noczyńska, A | 1 |
| Marzari, D | 1 |
| Bellone, J | 1 |
| Corrias, A | 1 |
| Chapurlat, RD | 2 |
| Orcel, P | 1 |
| Pfeilschifter, J | 1 |
| Ziegler, R | 1 |
| Bertelloni, S | 1 |
| Buzi, F | 1 |
| Rigon, F | 1 |
| Meunier, PJ | 1 |
| O'Sullivan, M | 1 |
| Zumkeller, W | 1 |
| Jassoy, A | 1 |
| Lebek, S | 1 |
| Nagel, M | 1 |
| Parisi, MS | 1 |
| Oliveri, MB | 1 |
| Mautalen, CA | 1 |
2 reviews available for pamidronate and Fibrous Dysplasia, Polyostotic
| Article | Year |
|---|---|
Fibrous dysplasia of bone and McCune-Albright syndrome.
Topics: Diphosphonates; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Fractures, Bone; GTP-Bind | 2008 |
Fibrous dysplasia of bone.
Topics: Adolescent; Anti-Inflammatory Agents; Diphosphonates; Fibrous Dysplasia of Bone; Fibrous Dysplasia, | 2000 |
4 trials available for pamidronate and Fibrous Dysplasia, Polyostotic
| Article | Year |
|---|---|
Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Topics: Adolescent; Adult; Alkaline Phosphatase; Body Height; Bone and Bones; Bone Density; Child; Diphospho | 2002 |
Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.
Topics: Adolescent; Adult; Alkaline Phosphatase; Anti-Inflammatory Agents; Bone and Bones; Bone Density; Bon | 2002 |
Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
Topics: Adolescent; Alkaline Phosphatase; Bone Density Conservation Agents; Child; Child, Preschool; Diphosp | 2006 |
Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Topics: Adolescent; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Fibrous Dysplasia of Bone | 2000 |
19 other studies available for pamidronate and Fibrous Dysplasia, Polyostotic
| Article | Year |
|---|---|
Giant Hemifacial Fibrous Dysplasia Functional Treatment and Place of Pamidronate.
Topics: Bone Density Conservation Agents; Child; Diphosphonates; Dose-Response Relationship, Drug; Facial Bo | 2017 |
Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
Topics: Adolescent; Diphosphonates; Disease Progression; Female; Femur; Fibrous Dysplasia, Polyostotic; Huma | 2017 |
EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Topics: Bone and Bones; Diphosphonates; Fibrous Dysplasia, Polyostotic; Humans; Pamidronate; Retrospective S | 2019 |
Craniofacial fibrous dysplasia: A 10-case series.
Topics: Adolescent; Adult; Aged; Bone Density Conservation Agents; Child; Diagnosis, Differential; Diphospho | 2017 |
Unusual phenotypical variations in a boy with McCune-Albright syndrome.
Topics: Base Sequence; Child; Diphosphonates; Fibrous Dysplasia, Polyostotic; Fractures, Bone; Growth Disord | 2010 |
Pamidronate for fibrous dysplasia due to McCune Albright Syndrome.
Topics: Ankle; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Fibrous Dy | 2010 |
Recurrent femur neck fracture and response to bisphosphonates in polyostotic fibrous dysplasia.
Topics: Adolescent; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Neck Fractures; Fibrou | 2012 |
[Fibrous dysplasia: differential diagnosis from Paget's disease].
Topics: Absorptiometry, Photon; Adult; Anti-Inflammatory Agents; Biopsy; Bone Diseases, Metabolic; Diagnosis | 2002 |
Precocious puberty: McCune-Albright syndrome and beyond.
Topics: Anti-Inflammatory Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Diphosphonates; | 2003 |
Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
Topics: Adolescent; Alkaline Phosphatase; Anti-Inflammatory Agents; Biomarkers; Biopsy; Body Height; Calcium | 2003 |
The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome.
Topics: Adolescent; Adult; Calcium; Child; Diphosphonates; Female; Fibroblast Growth Factor-23; Fibroblast G | 2005 |
Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
Topics: Adolescent; Bone and Bones; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonate | 2006 |
Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases.
Topics: Adult; Bone and Bones; Calcium; Diphosphonates; Female; Fetus; Fibrous Dysplasia, Polyostotic; Human | 2006 |
[A case of polyostotic fibrous dysplasia].
Topics: Aged; Anti-Inflammatory Agents; Diphosphonates; Female; Fibrous Dysplasia, Polyostotic; Humans; Pami | 2006 |
[Fibrous dysplasia of bone in a 12-year old girl].
Topics: Adolescent; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Fibro | 2006 |
[Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Bone and Bones; Child; Diphosphonates; Female; Fibrous | 1998 |
Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
Topics: Adolescent; Adult; Bone and Bones; Bone Density; Cardiac Output; Child; Child, Preschool; Diphosphon | 2000 |
Clinical, endocrinological and radiography features in a child with McCune-Albright syndrome and pituitary adenoma.
Topics: Adenoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Child; Diphosphonates; Drug Therapy | 2001 |
Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia.
Topics: Absorptiometry, Photon; Adult; Bone Density; Diphosphonates; Female; Fibrous Dysplasia, Polyostotic; | 2001 |